ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Size: px
Start display at page:

Download "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS"

Transcription

1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1

2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Meloxicam Excipients: Sodium benzoate 0.5 mg 1.5 mg For a full list of excipients, see section PHARMACEUTICAL FORM Pale yellow oral suspension. 4. CLINICAL PARTICULARS 4.1 Target species Dogs. 4.2 Indications for use, specifying the target species Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. 4.3 Contraindications Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients Do not use in dogs less than 6 weeks of age. 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Special precautions to be taken by the person administering the veterinary medicinal product to animals 2

3 People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 4.7 Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 4.8 Interaction with other medicinal products and other forms of interaction Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 4.9 Amounts to be administered and administration route Oral use. To be administered with food or directly into the mouth. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight (i.e. 4 ml/10 kg bodyweight) on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e. 2 ml/10 kg bodyweight). For longer term treatment, once clinical response has been observed (after 4 days), the dose can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time. Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using either of the two measuring syringes provided in the package. The syringes fit onto the bottle and have a kg-bodyweight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus for the first day, twice the maintenance volume will be required. Alternatively therapy may be initiated with Loxicom 5 mg/ml solution for injection. A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent. Avoid introduction of contamination during use Overdose (symptoms, emergency procedures, antidotes), if necessary In the case of overdose, symptomatic treatment should be initiated. 3

4 4.11 Withdrawal period Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams). ATCvet code: QM01AC Pharmacodynamic properties Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 5.2 Pharmacokinetic particulars Absorption Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. Distribution There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg. Metabolism Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Elimination Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium Benzoate Glycerol Povidone K30 Xanthan Gum Disodium Phosphate Dihydrate Sodium Dihydrogen Phosphate Dihydrate Citric Acid Anhydrous Simethicone Emulsion Purified water 4

5 6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 18 months Shelf-life after first opening the immediate packaging: 6 months 6.4 Special precautions for storage This veterinary medicinal product does not require any special storage conditions. 6.5 Nature and composition of immediate packaging The veterinary medicinal product is presented in 15 ml and 30 ml polyethylene terephthalate screw bottles with HDPE/LDPE child resistant caps. Two polyethylene/polypropylene measuring syringes, a 1 ml and a 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs. Each syringe is graduated in bodyweight, the 1 ml syringe is graduated from 0.25 kg to 5.0 kg and the 5 ml syringe for 1 kg to 25 kg. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co. Down, BT35 6JP United Kingdom 8. MARKETING AUTHORISATION NUMBER EU/2/08/090/001 EU/2/08/090/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10/02/2009 Date of last renewal: 12/03/ DATE OF REVISION OF THE TEXT Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency 5

6 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 6

7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 1.5 mg/ml oral suspension for dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Meloxicam Excipients: Sodium Benzoate 1.5 mg 1.5 mg For a full list of excipients, see section PHARMACEUTICAL FORM Pale yellow oral suspension. 4. CLINICAL PARTICULARS 4.1 Target species Dogs. 4.2 Indications for use, specifying the target species Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. 4.3 Contraindications Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do no use in dogs less than 6 weeks of age. 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Special precautions to be taken by the person administering the veterinary medicinal product to animals 7

8 People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 4.7 Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 4.8 Interaction with other medicinal products and other forms of interaction Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 4.9 Amounts to be administered and administration route Oral use. To be administered with food or directly into the mouth. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight (i.e ml/10 kg bodyweight) on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e ml/10 kg bodyweight). For longer term treatment, once clinical response has been observed (after 4 days), the dose can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time. Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using either of the two measuring syringes provided in the package (depending on weight of dog). The syringes fit onto the bottle and have a kg-bodyweight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus for the first day, twice the maintenance volume will be required. Alternatively therapy may be initiated with Loxicom 5 mg/ml solution for injection. A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent. Avoid introduction of contamination during use Overdose (symptoms, emergency procedures, antidotes), if necessary 8

9 In the case of overdose, symptomatic treatment should be initiated Withdrawal period(s) Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams). ATCvet code: QM01AC Pharmacodynamic properties Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 5.2 Pharmacokinetic particulars Absorption Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. Distribution There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg. Metabolism Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Elimination Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Sodium Benzoate Glycerol Povidone K30 Xanthan Gum Disodium Phosphate Dihydrate Sodium Dihydrogen Phosphate Dihydrate Citric Acid Anhydrous Simethicone Emulsion 9

10 Purified water 6.2 Incompatibilities None known. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 18 months Shelf-life after first opening the immediate packaging: 6 months 6.4 Special precautions for storage This veterinary medicinal product does not require any special storage conditions. 6.5 Nature and composition of immediate packaging The veterinary medicinal product is presented in 10 ml, 32 ml, 100 ml, 2 x 100 ml and 200 ml polyethylene terephthalate screw bottles with HDPE/LDPE child resistant caps. Two polyethylene/polypropylene measuring syringes, a 1 ml and 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs. Each syringe is graduated in bodyweight, the 1 ml syringe is graduated from 0.5 kg to 15 kg and the 5 ml syringe for 2.5 kg to 75 kg. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co Down, BT35 6JP United Kingdom 8. MARKETING AUTHORISATION NUMBER(S) EU/2/08/090/003 EU/2/08/090/004 EU/2/08/090/005 EU/2/08/090/032 EU/2/08/090/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10/02/2009 Date of last renewal: 12/03/ DATE OF REVISION OF THE TEXT 10

11 Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 11

12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 5 mg/ml solution for injection for dogs and cats. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Meloxicam Excipients: Ethanol, anhydrous 5 mg 150 mg For a full list of excipients, see section PHARMACEUTICAL FORM Pale yellow solution for injection. 4. CLINICAL PARTICULARS 4.1 Target species Dogs and cats. 4.2 Indications for use, specifying the target species Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery. 4.3 Contraindications Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg. 4.4 Special warnings for each target species For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia. 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. 12

13 Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. During anaesthesia, monitoring and fluid therapy should be considered as standard practice. Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported. In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported. In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. 4.7 Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 4.8 Interaction with other medicinal products and other forms of interaction Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 4.9 Amounts to be administered and administration route Dogs: Musculo-skeletal disorders: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight). Loxicom 1.5 mg/ml oral suspension and Loxicom 0.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection. Reduction of post-operative pain (over a period of 24 hours): Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia. Cats: 13

14 Reduction of post-operative pain in cats where no oral follow-up treatment is possible e.g. feral cats: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e ml/kg bodyweight) before surgery, for example at the time of induction of anaesthesia. In this case do not use oral follow up treatment. Reduction of post-operative pain in cats when administration of meloxicam is to be continued as an oral follow-up therapy: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e ml/kg body weight) before surgery, for example at the time of induction of anaesthesia. To continue treatment for up to five days, this initial dose may be followed 24 hours later by administration of Loxicom 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals.. Particular care should be taken with regard to the accuracy of dosing. A suitably graduated 1 ml syringe should be used for administration of the product to cats. Avoid introduction of contamination during use Overdose (symptoms, emergency procedures, antidotes), if necessary In the case of overdose, symptomatic treatment should be initiated Withdrawal period(s) Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams). ATCvet code: QM01AC Pharmacodynamic properties Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 5.2 Pharmacokinetic particulars Absorption Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 µg/ml in cats were reached approximately 2.5 hours and 1.5 hours post-administration, respectively. Distribution There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. More than 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats. Metabolism In dogs, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, 14

15 an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Elimination Meloxicam is eliminated with a half-life of 24 hours in dogs and 15 hours in cats. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Meglumine Glycine Ethanol (anhydrous) Poloxamer 188 Sodium Chloride Glycofurol Sodium Hydroxide (for ph adjustment) Hydrochloric Acid (for ph adjustment) Water for Injection 6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 18 months. Shelf-life after first opening the immediate packaging: 28 days 6.4 Special precautions for storage This veterinary medicinal product does not require any special storage conditions. 6.5 Nature and composition of immediate packaging Colourless glass injection vial of 10, 20 or 100 ml, closed with a bromobutyl stopper and sealed with an aluminium cap. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co Down, BT35 6JP United Kingdom 15

16 8. MARKETING AUTHORISATION NUMBER(S) EU/2/08/090/006 EU/2/08/090/007 EU/2/08/090/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10/02/2009 Date of last renewal: 12/03/ DATE OF REVISION OF THE TEXT Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 16

17 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for cats. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Meloxicam Excipient: Sodium benzoate 0.5 mg 1.5 mg For a full list of excipients, see section PHARMACEUTICAL FORM Pale yellow oral suspension. 4. CLINICAL PARTICULARS 4.1 Target species Cats. 4.2 Indications for use, specifying the target species Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in cats. 4.3 Contraindications Do not use in pregnant or lactating cats. Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients Do not use in cats less than 6 weeks of age. 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Post-operative pain and inflammation following surgical procedures: 17

18 In case additional pain relief is required, multimodal pain therapy should be considered. Chronic musculoskeletal disorders: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon. Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 4.7 Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 4.8 Interaction with other medicinal products and other forms of interaction Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously. 4.9 Amounts to be administered and administration route Oral use. To be administered with food or directly into the mouth. Shake well before use. Dosage Post-operative pain and inflammation following surgical procedures: After initial treatment with Loxicom 5 mg/ml Solution for Injection for Dogs and Cats continue treatment 24 hours later with Loxicom 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days. Acute musculo-skeletal disorders: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and inflammation persist. Chronic musculo-skeletal disorders: 18

19 Initial treatment is a single dose of 0.1 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg bodyweight. A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent. Dosing Procedure: The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required. For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4 times the maintenance volume will be required. Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded. The suspension should be given using the Loxicom measuring syringe provided in the package. Avoid introduction of contamination during use Overdose (symptoms, emergency procedures, antidotes), if necessary Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels. In the case of overdose, adverse reactions (as listed in Section 4.6) are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated Withdrawal period Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams). ATCvet code: QM01AC Pharmacodynamic properties Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 5.2 Pharmacokinetic particulars Absorption If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed. Due to the loading dose, steady is reached after 2 days (48h). Distribution There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. Metabolism 19

20 Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Elimination Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium Benzoate Glycerol Povidone K30 Xanthan Gum Disodium Phosphate Dihydrate Sodium Dihydrogen Phosphate Dihydrate Citric Acid Anhydrous Simethicone Emulsion Purified water 6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 18 months Shelf-life after first opening the immediate packaging: 6 months 6.4 Special precautions for storage This veterinary medicinal product does not require any special storage conditions. 6.5 Nature and composition of immediate packaging The veterinary medicinal product is presented in 5 ml, 15 ml and 30 ml polyethylene terephthalate screw bottles with HDPE/LDPE child resistant caps. The 1 ml measuring syringe has a kg-body weight scale for cats (0.5 to 10 kg). Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works 20

21 Newry Co. Down, BT35 6JP United Kingdom 8. MARKETING AUTHORISATION NUMBER EU/2/08/090/009 EU/2/08/090/027 EU/2/08/090/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10/02/2009 Date of last renewal: 12/03/ DATE OF REVISION OF THE TEXT Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 21

22 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 20 mg/ml solution for injection for cattle, pigs and horses. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active substance: Meloxicam 20 mg Excipient: Ethanol 150 mg For a full list of excipients, see section PHARMACEUTICAL FORM Solution for injection. A yellow solution. 4. CLINICAL PARTICULARS 4.1 Target species Cattle, pigs and horses. 4.2 Indications for use, specifying the target species Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves. Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy. Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic. 4.3 Contraindications See also section 4.7. Do not use in horses less than 6 weeks of age. Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions. Do not use in case of hypersensitivity to the active substance or to any of the excipients. 22

23 For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age. 4.4 Special warnings for each target species Treatment of calves with Loxicom 20 minutes before dehorning reduces post-operative pain. Loxicom alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed. 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity. In cases of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention. Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental self injection may cause pain. People with known hypersensitivity to Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Administration of the veterinary medicinal product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies In horses, a transient swelling at the injection site can occur but resolved without intervention. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. 4.7 Use during pregnancy, lactation or lay Cattle and Pigs: Can be used during pregnancy and lactation. Horses: Do not use in pregnant or lactating mares. See also section Interaction with other medicinal products and other forms of interaction Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents. 4.9 Amounts to be administered and administration route Cattle: Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e., 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate. The recommended maximum volume to be administered at a single injection site is 10 ml. 23

24 Pigs: Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e., 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours. The recommended maximum volume to be administered at a single injection site is 2 ml. Horses: Single intravenous injection as a dosage of 0.6 mg meloxicam/kg body weight (i.e., 3.0 ml/100 kg body weight). For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders, a suitable oral therapy containing meloxicam, administered in accordance with label recommendations, may be used for continuation of treatment. Avoid introduction of contamination during use. Do not exceed 50 broachings per vial. If more than 50 broachings are required, the use of a draw-off needle is recommended Overdose (symptoms, emergency procedures, antidotes), if necessary In the case of overdose, symptomatic treatment should be initiated Withdrawal period Cattle: Meat and offal: 15 days Milk: 5 days Pigs: Meat and offal: 5 days Horses: Meat and offal: 5 days. Not authorised for use in horses producing milk for human consumption. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams) ATC vet code: QM01AC Pharmacodynamic properties Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B 2 induced by E. coli endotoxin administration in calves, lactating cows and pigs. 5.2 Pharmacokinetic particulars Absorption After a single subcutaneous dose of 0.5 mg meloxicam/kg, C max values of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively. After two intramuscular doses of 0.4 mg meloxicam/kg, a C max value of 1.9 μg/ml was reached after 1 hour in pigs. Distribution More than 98% of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat. Metabolism 24

25 Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated. Elimination Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively. In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours. In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours. Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients - Ethanol - Meglumine - Glycine - Poloxamer Sodium chloride - Macrogol Hydrochloric acid - Sodium hydroxide - Water for injections 6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life after first opening the immediate packaging: 28 days. 6.4 Special precautions for storage This veterinary medicinal product does not require any special storage conditions. 6.5 Nature and composition of immediate packaging Cardboard box with either 1 or 12 colourless glass injection vial(s) each containing 30 ml, 50 ml or 100 ml. Cardboard box with 1, 6 or 12 colourless glass injection vial(s) each containing 250 ml. Each vial is closed with a bromobutyl bung and sealed with an aluminium cap. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products 25

26 Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co Down, BT35 6JP United Kingdom 8. MARKETING AUTHORISATION NUMBERS: EU/2/08/090/ ml EU/2/08/090/ ml EU/2/08/090/ ml EU/2/08/090/ ml EU/2/08/090/014 6 x 250 ml EU/2/08/090/ x 30 ml EU/2/08/090/ x 50 ml EU/2/08/090/ x 100 ml EU/2/08/090/ x 250 ml 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10/02/2009 Date of last renewal: 12/03/ DATE OF REVISION OF THE TEXT Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 26

27 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 1 mg chewable tablets for dogs Loxicom 2.5 mg chewable tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains: Active substance: Meloxicam 1 mg Meloxicam 2.5 mg For a full list of excipients, see section PHARMACEUTICAL FORM Chewable tablet. Light brown oval biconvex tablet with a score line on one face and plain on the other. The tablets can be broken into equal halves. 4. CLINICAL PARTICULARS 4.1 Target species Dogs 4.2 Indications for use, specifying the target species Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. 4.3 Contraindications Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders Do not use in dogs less than 6 weeks of age or less than 4 kg body weight. Do not use in case of hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings for each target species None 4.5 Special precautions for use Special precautions for use in animals If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. This veterinary medicinal product for dogs should not be used in cats as it is not suitable for use in this species. In cats, a meloxicam containing oral suspension authorised for that species should be used. 27

28 Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 4.7 Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 4.8 Interaction with other medicinal products and other forms of interaction Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. This veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the veterinary medicinal products used previously. 4.9 Amounts to be administered and administration route Oral use. Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. Alternatively, therapy may be initiated with a solution for injection containing 5 mg meloxicam/ml. Each chewable tablet contains 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog, respectively. Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. The tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily. Dose scheme for the maintenance dose: 28

29 Body weight (kg) Number of chewable tablets 1 mg Number of chewable tablets 2.5 mg mg/kg ½ ½ ½ The use of a meloxicam containing oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of meloxicam containing oral suspension for dogs is recommended. A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent. To ensure correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing or overdosing Overdose (symptoms, emergency procedures, antidotes), if necessary In case of overdose, symptomatic treatment should be initiated Withdrawal period Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams), ATC vet code: QM01AC Pharmacodynamic properties Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 5.2 Pharmacokinetic properties Absorption Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the veterinary medicinal product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. Distribution 29

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml

More information

Metacam 1.5 mg/ml oral suspension for dogs

Metacam 1.5 mg/ml oral suspension for dogs Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.

SUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Acticam 1.5

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Novem 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs. EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (United Kingdom, Germany, Iceland)

More information

PART 1 B1 SUMMARY OF PRODUCT CHARACTERISTICS (SPC)

PART 1 B1 SUMMARY OF PRODUCT CHARACTERISTICS (SPC) PART 1 B1 SUMMARY OF PRODUCT CHARACTERISTICS (SPC) SPC for Acticam 1 mg Chewable Tablets for dogs and Acticam 2.5mg Chewable Tablets for dogs are presented in subsequent pages, SPC for Acticam 1 mg Chewable

More information

Veterinary Medicinal Product

Veterinary Medicinal Product Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs

More information

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin 50 mg/g Oral paste for horses (DE, AT, BE, EE, LV, LT, ES, FR, IE, IT, NL, PL, UK) Cronyxin vet

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

The new meloxicam range for cattle, pigs & horses

The new meloxicam range for cattle, pigs & horses The new meloxicam range for cattle, pigs & horses Melovem 5 mg/ml Melovem 20 mg/ml Melovem 30 mg/ml The new Melovem range + Many indications for cattle, horses and pigs + Accurate dosing Dopharma has obtained

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DINALGEN 60 mg/ml solution for injection for pigs (all countries except FI and SE) DINALGEN VET 60 mg/ml solution for injection

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE

More information

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Scientific Discussion post-authorisation update for Rheumocam extension X/007 5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)

More information

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Maprelin 75 µg/ml solution for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carofertin 10 mg/ml Emulsion for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oxycare 20 %w/v LA Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Oxytetracycline (Equivalent

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylacare 2% w/v Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Qualitative composition

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Revised: March 2015 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tolracol 50 mg/ml oral suspension for pigs, cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of Veterinary Medicinal Product Endofluke 100 mg/ml Oral Suspension 2. Qualitative and Quantitative Composition Active Substance per ml Triclabendazole 100mg

More information

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

1. NAME OF THE VETERINARY MEDICINAL PRODUCT Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Distocur 34 mg/ml Oral suspension for cattle. Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE) 2.

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 5% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Clostanel sodium)

More information

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption. A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT EQUIOXX 8.2 mg/g oral paste for horses. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each syringe contains 7.32 g

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Issued March 2017 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats Recicort vet 1.77 mg/ml + 17.7 mg/ml

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Streptacare Suspension for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Each ml contains: Procaine

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pneumospectin 50 mg/ml +100 mg/ml solution for injection for cattle (calves), sheep, goat, pig,

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amphen 200 mg/g Granules for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains: Active

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oncept IL-2 lyophilisate and solvent for suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance

More information

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including: SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pro Penstrep Suspension for Injection for Cattle, Sheep and Pigs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cefenil 50 mg/ml Powder and Solvent for Solution for Injection for and. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Powder vial

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur PetPaste 187.5 mg/g oral paste for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g oral

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BLUEVAC BTV8 suspension for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, CZ, EE, ES, FR, IE, IS, IT, LT, LU, LV, NO, PL, PT, RO, SE, SI, SK, UK: Genestran 75 micrograms/ml solution for injection

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Revised: January 2012 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Blackleg Vaccine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s): per ml Five strains

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidolor 5 mg/ml solution for injection for dogs, cats, cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Credelio 56 mg chewable tablets for dogs (1.3 2.5 kg) Credelio 112 mg chewable tablets for dogs (>2.5 5.5 kg) Credelio

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2-4 kg NexGard 28 mg chewable tablets for dogs > 4-10 kg NexGard 68 mg chewable

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection SUMMARY OF PRODUCT CHARACTERISTICS Revised: June 2018 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Valbazen 100 mg/ml Total Spectrum Wormer 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance Albendazole

More information

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ubroseal Dry Cow 2.6 g intramammary suspension for cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 4g intramammary

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCPCh lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis ColiClos suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ketink 100 mg/ml solution for injection for cattle, horses and pigs [Austria, Bulgaria, Cyprus, Czech Republic, Estonia, France,

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT IVOMEC Injection for Pigs 10 mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Ivermectin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the Veterinary Medicinal Product Vetofol 10mg/ml Emulsion for Injection for cats and dogs (AT, CY, EE, FI, DE, EL, LV, PT, ES) Norofol 10mg/ml Emulsion for

More information

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1. 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Covexin 8 Suspension for injection for sheep and cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Potency value/quantity/ml C. perfringens

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tilmovet 250 mg/ml Concentrate for Oral Solution (BE, BG, CZ, EL, HU, IE, NL, PL, RO, UK) for pigs, chickens, turkeys and

More information

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMPROLINE 400 mg/ml solution for use in drinking water for chickens and turkeys 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

SUMMARY OF THE PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS 1 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Exflow 10 mg/g powder for use in drinking water for cattle (calves), pigs, chickens, turkeys and ducks Exflow Vet 10

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS [Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY

More information

LABELLING AND PACKAGE LEAFLET

LABELLING AND PACKAGE LEAFLET LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection

More information

LUTEOSYL(d)-Cloprostenol mg/ml Solution for injection for cattle and pigs

LUTEOSYL(d)-Cloprostenol mg/ml Solution for injection for cattle and pigs SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In France, Germany, Hungary, Italy, Poland, Spain and The Netherlands; LUTEOSYL 0.075 mg/ml

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Metacam, Solution for injection 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Metacam solution

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 50 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Closantel

More information